InnoSlim® has demonstrated in NuLiv Science in-vitro, in-vivo, and human studies to have promising effects on reducing fasting glucose levels and improving metabolic function in tested subjects. These studies suggest that InnoSlim® could achieve this by activating a specific pathway called the adiponectin and AMPK signaling pathway, which plays a role in regulating the levels of fats and sugar in the bloodstream.

Decreased levels of adiponectin are linked to difficulties in regulating blood sugar and breaking down fatty acids. Adiponectin functions by controlling the cellular energy metabolism through the regulation of the AMPK signaling pathway. When adiponectin levels increase, there is a subsequent rise in AMPK phosphorylation, which promotes the breakdown of fatty acids. Additionally, AMPK enhances the regulation of a glucose transporter called GLUT4 in muscle and fat tissues, leading to increased glucose uptake and improved metabolic function.

By supporting adiponectin levels and secretion in fat cells, InnoSlim® works to stimulate the phosphorylation and activation of AMPK in skeletal muscles. This activation is followed by the activation of GLUT4 and increased phosphorylation of ACC, resulting in the breakdown of fatty acids and uptake of glucose in muscle cells. These effects have been observed in in-vitro and in-vivo studies conducted by NuLiv Science.^{1, 2, 3} Moreover, human clinical trials have further supported these findings by demonstrating that InnoSlim® may promote the adiponectin and AMPK signaling pathway in tested subjects, supporting metabolic wellness measured by a couple of key biomarkers.^{4, 5}

*These statements may not comply with your country’s laws and regulations or with Reg. EC n. 1924/2006 and have not been evaluated by the Food and Drug Administration. The products are not intended to diagnose, treat, cure or prevent any disease. Marketers of finished products containing this ingredient are responsible for ensuring compliance with the applicable legal framework.